in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Boehringer Ingelheim Builds API Facility in U.S.
6:39 AM MST | November 28, 2011 | Deepti Ramesh
Boehringer Ingelheim (Ingelheim, Germany) says its Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT) subsidiary is building a $65-million facility that will produce active pharmaceutical ingredients (APIs) used in early development activities. Products developed here, if approved, will move on to Boehringer Ingelheim’s full-scale R&D facilities in Ohio and Virginia in the U.S., as well as in Germany and Italy. The project will “increase Boehringer Ingelheim’s research and development capabilities and reinforce our commitment to growth...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee